Minapharm Pharmaceuticals (CAI:MIPH) ROCE % : 6.33% (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Minapharm Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minapharm Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2024 was 6.33%.

Minapharm Pharmaceuticals ROCE % Historical Data

The historical data trend for Minapharm Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minapharm Pharmaceuticals ROCE % Chart

Minapharm Pharmaceuticals Annual Data

Trend

Dec22

Dec23

ROCE %

21.89

6.07

Minapharm Pharmaceuticals Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
ROCE %	-	14.68	-1.10	6.33

Minapharm Pharmaceuticals ROCE % Calculation

Minapharm Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	287.486	/	( ( (6805.891 - 2500.647)	+	(8703.565 - 3531.005) )	/ 2 )
	=	287.486	/	( (4305.244	+	5172.56)	/ 2 )
	=	287.486	/	4738.902
	=	6.07 %

Minapharm Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	369.272	/	( ( (8703.565 - 3531.005)	+	(11269.764 - 4783.61) )	/ 2 )
	=	369.272	/	( ( 5172.56	+	6486.154 )	/ 2 )
	=	369.272	/	5829.357
	=	6.33 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Minapharm Pharmaceuticals (CAI:MIPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minapharm Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Minapharm Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY

Website

https://www.minapharm.com

Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

Minapharm Pharmaceuticals Headlines

No Headlines